Literature DB >> 8736150

Severe forms of neurocysticercosis: treatment with albendazole.

S Agapejev1, M D Da Silva, A K Ueda.   

Abstract

Study of 22 patients with the severe form of neurocysticercosis treated with albendazole (ABZ) administered in 6 different schedules ranging from 15 to 30 mg/kg/day for 21 to 60 days. Dextrochloropheniramine and ketoprofen were the adjuvant drugs. Multiple symptoms were observed in 90.9% of patients. Intracranial hypertension was manifested in 90.9%. Hydrocephaly occurred in 86.4%. Evolution was satisfactory in 10 patients, 8 died and 4 had sequelae. Tomographic studies showed the appearance of an isolated IVth ventricle in 9 patients, after ventriculoperitoneal shunt, before ABZ treatment in 3 of them, during in 5 and after treatment in one. Median clinical follow-up duration was 10 months for the patients who died and 3-4 years for survivors. In 3 patients there was an increase in cyst size during the administration of the 15 mg/kg/day ABZ dose, which was not observed in any patient when the 30 mg/kg/day dose was used.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8736150     DOI: 10.1590/s0004-282x1996000100014

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  10 in total

1.  Intraventricular and subarachnoid basal cisterns neurocysticercosis: a comparative study between traditional treatment versus neuroendoscopic surgery.

Authors:  Jefferson V Proaño; Jaime Torres-Corzo; Roberto Rodríguez-Della Vecchia; Gabriel Guizar-Sahagun; Leonardo Rangel-Castilla
Journal:  Childs Nerv Syst       Date:  2009-06-26       Impact factor: 1.475

Review 2.  Diagnosis and treatment of neurocysticercosis.

Authors:  Theodore E Nash; Hector H Garcia
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

Review 3.  Current status and future perspectives on the medical treatment of neurocysticercosis.

Authors:  Isidro Gonzales; Hector H Garcia
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

4.  The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis.

Authors:  Kriti Thapa; Matthew L Romo; Arturo Carpio; Denise Leslie; Howard Andrews; W Allen Hauser; Elizabeth A Kelvin
Journal:  Trans R Soc Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.184

Review 5.  Hydrocephalus in neurocysticercosis.

Authors:  Hamilton Matushita; Fernando Campos Gomes Pinto; Daniel Dante Cardeal; Manoel Jacobsen Teixeira
Journal:  Childs Nerv Syst       Date:  2011-09-17       Impact factor: 1.475

Review 6.  Corticosteroid use in neurocysticercosis.

Authors:  Theodore E Nash; Siddhartha Mahanty; Hector H Garcia
Journal:  Expert Rev Neurother       Date:  2011-08       Impact factor: 4.618

Review 7.  Current consensus guidelines for treatment of neurocysticercosis.

Authors:  Hector H García; Carlton A W Evans; Theodore E Nash; Osvaldo M Takayanagui; A Clinton White; David Botero; Vedantam Rajshekhar; Victor C W Tsang; Peter M Schantz; James C Allan; Ana Flisser; Dolores Correa; Elsa Sarti; Jon S Friedland; S Manuel Martinez; Armando E Gonzalez; Robert H Gilman; Oscar H Del Brutto
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

8.  Natural History of Treated Subarachnoid Neurocysticercosis.

Authors:  Theodore E Nash; Elise M O'Connell; Dima A Hammoud; Lauren Wetzler; JeanAnne M Ware; Siddhartha Mahanty
Journal:  Am J Trop Med Hyg       Date:  2020-01       Impact factor: 2.345

Review 9.  Subarachnoid neurocysticercosis: emerging concepts and treatment.

Authors:  Theodore E Nash; Elise M O'Connell
Journal:  Curr Opin Infect Dis       Date:  2020-10       Impact factor: 4.968

10.  Reversible dementia due to neurocysticercosis: Improvement of the racemose type with antihistamines.

Authors:  Gislaine Cristina Lopes Machado-Porto; Leandro Tavares Lucato; Fábio Henrique de Gobbi Porto; Evandro Cesar de Souza; Ricardo Nitrini
Journal:  Dement Neuropsychol       Date:  2015 Jan-Mar
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.